Beijing Sun-Novo Pharmaceutical Research688621.SHValuation Analysis

As of Oct 19, 2026, Beijing Sun-Novo Pharmaceutical Research (688621.SH) trades at a P/E of 137.00x, P/B of 5.70x, P/S of 7.97x, and a dividend yield of 0.30%.
Longitudinal percentile comparison: P/E sits at the 95th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/B sits at the 29th percentile over the trailing 10Y window (vs. 51st percentile over 3Y); P/S sits at the 52nd percentile over the trailing 10Y window (vs. 76th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 86th percentile within its industry and the 86th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.77%, ranking at the 94th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 65.4 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 0.30% comes from cash dividends, with an implied ~1.47% from buybacks — a fairly balanced mix of both channels. Beijing Sun-Novo Pharmaceutical Research operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.